Albany, NY -- (SBWIRE) -- 01/13/2020 -- Allergic Rhinitis Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Allergic Rhinitis Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report
1. Rhinitis affects about 40% of western populations, and 25–50 % of patients with Rhinitis are non-allergic.
2. Allergic Rhinitis prevalence peaks around the age of 16–24 and decreases in the subsequent years up to the age of 65–70.
3. Allergic Rhinitis affects nearly 60 million people in the United States, with approximately 80% of those diagnosed with the disease developing symptoms before age 20 years.

Key benefits of the report
1. Allergic Rhinitis market report covers a descriptive overview and comprehensive insight of the Allergic Rhinitis epidemiology and Allergic Rhinitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Allergic Rhinitis market report provides insights on the current and emerging therapies.
3. Allergic Rhinitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Allergic Rhinitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Allergic Rhinitis market.

Request for sample pages

"Allergic rhinitis prevalence for the male-female ratio was 1.25 in children, 0.80 in adolescents and 0.98 in adults."

Allergic rhinitis can be treated in various ways; medications, home remedies and alternative medicines. Medications include use of antihistamines, decongestants, eye drops and nasal sprays, immunotherapy and Sublingual immunotherapy (SLIT). The use of antibiotics and nasal surgery is not recommended. The second- generation of antihistamines (nonsedating) are preferable to inhibit sedation and other severe effects that are associated with the older, first-generation antihistamines.
The mainstay of allergic rhinitis treatment is Intranasal corticosteroids. Its mechanism is that it decreases the incoming of inflammatory cells and preventing the release of the cytokine, thereby reducing inflammation of the nasal mucosa.
Histamine is in an early allergic response. The first-generation antihistamines cover brompheniramine, chlorpheniramine, clemastine, and diphenhydramine (Benadryl). When compared with first-generation antihistamines, second-generation antihistamines have a better adverse-effect profile and cause less sedation, except cetirizine (Zyrtec). The second-generation oral antihistamines cover desloratadine (Clarinex), levocetirizine (Xyzal), fexofenadine (Allegra), and loratadine.

The key players in Allergic Rhinitis market are:
1. Inmunotek S.L.
2. Regeneron Pharmaceuticals
And many others

Table of contents
1. Key Insights
2. Allergic Rhinitis Market Overview at a Glance
3. Allergic Rhinitis Disease Overview
4. Allergic Rhinitis Epidemiology and Patient Population
5. Country Wise Allergic Rhinitis Epidemiology
5.1. United States
5.2. EU5
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Allergic Rhinitis Treatment Practices
7. Allergic Rhinitis Treatment Guidelines and Recommendations
8. Allergic Rhinitis Treatment Algorithm
9. Unmet Needs
10. Allergic Rhinitis Emerging Therapies
10.1.Key cross competition- Emerging Therapies
10.2. Regeneron Pharmaceuticals
11. Allergic Rhinitis 7 Major Market Analysis
12. Market Outlook by Country
13. The United States: Market Outlook
13.1.United States Market Size
14. EU-5 Countries: Market Outlook
14.1.Germany
14.2.France
14.3.Italy
14.4.Spain
14.5.United Kingdom
14.6.Japan: Market Outlook
15. Market Drivers
16. Market Barriers
17. Appendix
17.1. Allergic Rhinitis Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight